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Use of recombinant factor VIIa for emergency reversal Use of recombinant factor VIIa for emergency reversal Use of recombinant factor VIIa for emergency reversal Use of recombinant factor VIIa for emergency reversal Use of recombinant factor VIIa for emergency reversal of anticoagulation of anticoagulation of anticoagulation of anticoagulation of anticoagulation A such as warfarin, acenocoumarol (coumarin), unfractionated heparin (UFH) and low molecular weight heparins (LMH). Patients on anticoagulation therapy may require rapid reversal of anticoagulation in the event of life-threatening hemorrhage or when invasive procedures need to be undertaken. Currently available methods of reversal have serious limitations or are beset with several disadvantages. For example, Vitamin K reverses the effects of warfarin and coumarin, but takes several hours to achieve clinical effect. More rapid reversal of anticoagulation may be achieved by infusion of either freshfrozen plasma (FFP) or prothrombin complex concentrates (PCCs). However, these agents are inconsistent in their action on INR or PTT, require a long time for commencement of effect See editorial on page no. 3, 4
thrombogenic.
[1] Protamine can reverse the effects of UFH, but has limited ability in reversing the anticoagulant effects of LMWH and also carries a risk of allergic reactions.
[2,3] FVIIa (rFVIIa) (NovoSeven ® ; Novo Nordisk A/S, Bagsvaerd, Denmark) has the potential to act as a hemostatic agent in patients requiring anticoagulant reversal. Although there are reports citing its use in the management of acute hemorrhage in situations such as platelet disorders, [4] [5] [6] congenital FVII deficiency, [7] cardiac surgery, [8] trauma, [9] intracerebral bleeding, [10] liver transplantation [11] and obstetric practice, [12] there is only a case report describing the use of rFVIIa for heparin reversal. [16] As ethical and practical difficulties preclude a systematic study of a new drug in patients suffering from clinically significant anticoagulant-related hemorrhage, this study was undertaken to collate the experiences of a number of physicians using rFVIIa. 
Materials and Methods
Haemostasis.com is an international, internet-based registry established to gather voluntarily submitted data on the investigational use of rFVIIa.
[17] It is independently managed and supervised by a steering committee of medical experts. Individual physicians entered information regarding off-label use of rFVIIa onto the haemostasis.com website between June 2001 and December 2003 using a password. An automated search of the registry was undertaken to identify all cases of anticoagulation-related bleeding treated with rFVIIa using the search term 'coagulopathy, anticoagulant reversal, other'. These 87.35 µg/kg (range: 20.0-106.0 µg/kg. All but one patient received a single dose of rFVIIa.
Efficacy
Treatment with rFVIIa was associated with cessation of bleeding in ten cases. Bleeding was markedly decreased in another five, while it slowed considerably in three patients. In 12/16 patients, improved hemostasis occurred within two hours of receiving a single dose of rFVIIa (interval not recorded in one patient). In patient 15, response was observed within two hours of the second dose. Neither the initial severity of the bleed, nor the dose of rFVIIa administered appeared to records were manually cross-checked against monthly summary determine the efficacy of treatment. reports of new entries, produced by the registry administrator.
Administration of other agents Case providers were requested to complete a registry template
Half the patients included on the haemostasis.com website and provide the following anticoagulation antidotes other than rFVIIa. There was no information: patient age, sex, actual body weight and indication that the administration of these agents influenced underlying condition; bleeding severity (subjectively classed the overall bleeding outcome. Seventeen patients were infused as mild, moderate or severe); all medications administered, replacement blood products (packed cells, whole blood, FFP, including platelet transfusions before and after rFVIIa cryoprecipitate or platelets) and 12 patients received administration; dosage of rFVIIa, number of doses and crystalloids or colloids in the 24h before rFVIIa administration. interval between doses; bleeding response to rFVIIa
The use of replacement blood products (P<0.001) and fluid (subjectively classed as stopped, markedly decreased, slowed, therapy (P< 0.05) were significantly reduced in the 24h after no change, increased) and time to response; adverse events administration of rFVIIa [ Figure 1 ]. and whether these were related to rFVIIa; results of laboratory tests (Hb, INR Patients 1 and 3 underwent cardiac surgery during establishment As no formal clinical investigation was undertaken and of extracorporeal circulation (ECC); UFH was administered peri haemostasis.com serves only as a repository, ethical committee operatively to prevent ECC-related clotting. In these subjects approval was not sought. The primary outcome under pre and postsurgery APTTs values increased from 34s to 76s and examination was cessation of hemorrhage. Secondary outcomes from 38s to 57s respectively after receiving rFVIIa. changes in fluid requirement and hematological parameters. The Wilcoxon signed rank test was used to Three of six patients receiving LMWH had evidence of compare administration of blood products and crystalloids/ colloids during the 24h before and after injection of rFVIIa, as well as changes in clotting factors.
in this series received were Details of 18 patients entered into haemostasis.com who experienced anticoagulant-related bleeding treated with rFVIIa are presented here.
Results
A search of haemostasis.com identified 27 patients satisfying the inclusion criteria. All of them received rFVIIa as a rescue therapy for bleeding during or after a surgical or invasive procedure. Nine patients were excluded because it was not possible to validate results and/or obtain permission for their inclusion from the case providers. However, the demographic characteristics of cases not included were quite similar to the group of patients included. The patient and treatment characteristics of the 18 patients analyzed are summarized in Table 1 . These patients received a median dose of rFVIIa of . c o m ) . Figure 2: International normalized ratio (INR) before and after rFVIIa administration (n = 11); P < 0.01 (overall; Wilcoxon signed rank test). Fibrinogen levels generally increased following IV rFVIIa (preadministration: median, 2.7 g/l; range, 0.5-5.1 g/l; n = 12; postadministration: median, 3.5 g/l; range, 1.6-6.0 g/l; n = 10). Similarly, hemoglobin levels rose in the majority of subjects (preadministration: median, 9.1 g/dl; range, 5.3-13.9 g/dl; n = 17; postadministration: median, 10.03 g/dl; range, 7.0-12.8 g/dl; n =17).
*Lines represent data on two patients each

Final outcome
Final outcome was recorded in 14 patients: eight patients were discharged from the hospital, one patient remained in intensive care and five patients died (multiple organ failure: two, cardiac failure, hemorrhagic shock and undetermined cause one each). Adverse events All deaths were considered to be 'unrelated to rFVIIa' Ingerslev, et al.: rFVIIa in anticoagulation � administration. rFVIIa was well tolerated and no adverse events were reported.
Discussion
rFVIIa is thought to act primarily by binding to the surface of activated platelets at the site of injury leading to the formation of a stable, localized clot. It was originally developed for the treatment of bleeding episodes in patients with hemophilia A or B. Limited data available indicates that rFVIIa could be of value in emergency anticoagulant reversal in a wide range of clinical situations. Various studies have shown that it is effective was effective in all but one patient and at slightly lower dosages than those recommended for hemophilia (median dose: 87.35 µg/kg body weight). In one subject (Patient 10), a small dose (20.0 µg/kg) proved sufficient to achieve hemostasis, a dose consistent with that recommended by some authors. [22] In a series of 16 patients presenting with a major bleeding event concurrent with use of warfarin, a single dose of 1.2 mg of rFVIIa at 16.3 ± 4.1 µg/kg normalized the INR in all patients and was clinically efficacious in 14 of 16 patients. [23] It should be noted that patients included in the present study did not receive some of the latest generation of anticoagulants. Agents such as danaparoid sodium and fondaparinux, which in normalizing PT and controlling warfarin-induced bleeding predominantly or exclusively have anti-FXa activity, currently in animal models, [13] normalizing INR and PT in healthy lack a specific antidote. volunteers receiving acenocoumarol, decreasing INR in nontraumatic, warfarin-related acute intracranial
In this study, rFVIIa was well tolerated and no adverse events hemorrhage [14] and preventing bleeding when administered were reported. Whilst the mechanism of action of rFVIIa has prophylactically to patients with deficiency of vitamin Knot been fully elucidated, [24] there is a potential risk of dependent factors. [15] thromboembolic events. [26] [27] [28] This study suggests that administration of rFVIIa may be of Thus, the study suggests that rFVIIa can control severe value in anticoagulated subjects suffering significant bleeding in patients receiving a variety of anticoagulant hemorrhage unresponsive to conventional measures. Our therapies that is unresponsive to traditional antidotes. findings need to be interpreted with care in view of a number Additional benefits may include fewer side-effects compared of methodological limitations and difficulties in establishing to other haemostatic agents and in certain circumstances more a direct link between rFVIIa and hemostasis. Patients in this cost-effective management (e.g., when compared to APCC). series are heterogeneous (receipt of different anticoagulants It is worthwhile to consider undertaking research to determine and other therapies, voluntary registration of subjects which the efficacy and safety and define optimal dosing of rFVIIa in may have led to a bias in enrolment and presence of incomplete anticoagulated subjects. or subjective data with regards to degree of bleeding). On the plus side, our hypothesis is supported by the fact that prior References hemostatic treatments were unsuccessful, clotting parameters generally improved and there was a significant decrease in of the current absence of a reliable antidote to LMWH and 5 Almeida AM, Khair K, Hann I, Liesner R. The use of recombinant the agent's long half-life. Protamine is commonly used to reverse the effects of UFH therapy, but is less reliable for LMWH.
[18] Clinical benefit was also seen in patients who had received UFH and/or coumarin. Our experience of reversing the effects of warfarin are supported by a study from Deveras and Kessler, [19] who showed that rFVIIa successfully reversed the effects of excessive warfarin anticoagulation in 13 patients. In four of these patients who were actively bleeding, hemorrhage stopped immediately after rFVIIa administration. We note that a recent study favored continuous intravenous infusion of rFVIIa over intravenous bolus administration for patients deficient in Factor VII and undergoing surgery.
[20]
The dose required to achieve hemostasis varies according to different reports. For patients with hemophilia A or B, the typical dose of rFVIIa is in the range 90-110 µg/kg every 2-3h until cessation. [21] In the current study, a single dose of rFVIIa ) .
